AimedBio: Tech Transfer Revenue Surges, but R&D Costs Widen Loss

Revenue surged to 8,498M KRW (Q1 2025: 1,581M KRW) driven by tech transfer income of 8,380M KRW (0 in prior year period)
Net loss widened to 2,010M KRW (Q1 2025: 1,063M KRW) as R&D spending increased to 12,455M KRW (147% of revenue)
After KOSDAQ listing in Dec 2025, holds total financial assets of 170.5B KRW including cash 11.8B KRW and ST financial instruments 64.4B KRW
Pipeline: AMB302 (FGFR3 ADC) in Phase 1 in US; AMB303 (ROR1 ADC) and ODS025 (undisclosed target) in IND-enabling stages
Key agreements: tech transfer/licensing with Biohaven, SK Plasma, and Boehringer Ingelheim
No BIS ratio, NPL, or contingent liabilities disclosed (not applicable)
No share buyback, cancellation, or dividend mentioned